Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | May 08, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | Diffusion Pharmaceuticals Inc. | |
Entity Central Index Key | 0001053691 | |
Trading Symbol | dffn | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 3,379,345 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 5,333,714 | $ 7,991,172 |
Prepaid expenses, deposits and other current assets | 1,050,008 | 923,059 |
Total current assets | 6,383,722 | 8,914,231 |
Property and equipment, net | 332,009 | 350,281 |
Intangible asset | 8,639,000 | 8,639,000 |
Right of use asset | 313,364 | |
Other assets | 319,724 | 298,480 |
Total assets | 15,987,819 | 18,201,992 |
Current liabilities: | ||
Accounts payable | 480,016 | 198,818 |
Accrued expenses and other current liabilities | 603,448 | 605,226 |
Current operating lease liability | 110,001 | |
Total current liabilities | 1,193,465 | 804,044 |
Deferred income taxes | 1,636,037 | 1,786,389 |
Noncurrent operating lease liability | 203,363 | |
Total liabilities | 3,032,865 | 2,590,433 |
Commitments and Contingencies (Note 7) | ||
Stockholders’ Equity: | ||
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 3,376,230 shares issued and outstanding at March 31, 2019 and December 31, 2018. | 3,377 | 3,377 |
Additional paid-in capital | 95,624,085 | 95,532,881 |
Accumulated deficit | (82,672,508) | (79,924,699) |
Total stockholders' equity | 12,954,954 | 15,611,559 |
Total liabilities and stockholders' equity | $ 15,987,819 | $ 18,201,992 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 3,376,230 | 3,376,230 |
Common stock, shares outstanding (in shares) | 3,376,230 | 3,376,230 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating expenses: | ||
Research and development | $ 1,699,845 | $ 1,825,568 |
General and administrative | 1,200,728 | 1,497,839 |
Depreciation | 18,272 | 28,018 |
Loss from operations | 2,918,845 | 3,351,425 |
Other income: | ||
Interest income | (20,684) | (37,464) |
Loss from operations before income tax benefit | (2,898,161) | (3,313,961) |
Income tax benefit | (150,352) | |
Net loss | (2,747,809) | (3,313,961) |
Series A cumulative preferred dividends | (85,993) | |
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common stock | (8,167,895) | |
Net loss attributable to common stockholders | $ (2,747,809) | $ (11,567,849) |
Per share information: | ||
Net loss per share of common stock, basic and diluted (in dollars per share) | $ (0.81) | $ (4.11) |
Weighted average shares outstanding, basic and diluted (in dollars per share) | $ 3,376,230 | $ 2,814,316 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 8,306,278 | 967,976 | |||
Balance at Dec. 31, 2017 | $ 968 | $ 82,783,865 | $ (61,554,889) | $ 21,229,944 | |
Conversion of Series A convertible preferred stock to common stock (in shares) | (8,306,278) | 553,752 | |||
Conversion of Series A convertible preferred stock to common stock | $ 554 | (554) | |||
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature (in shares) | 777,895 | ||||
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature | $ 778 | (778) | |||
Issuance of common stock related to accrued dividends (in shares) | 68,815 | ||||
Issuance of common stock related to accrued dividends | $ 69 | 1,148,238 | 1,148,307 | ||
Series A cumulative preferred dividends | (85,993) | (85,993) | |||
Issuance of common stock and warrants, net of issuance costs (in shares) | 1,000,000 | ||||
Issuance of common stock and warrants, net of issuance costs | $ 1,000 | 10,416,520 | 10,417,520 | ||
Stock-based compensation expense | 324,667 | 324,667 | |||
Net loss | (3,313,961) | (3,313,961) | |||
Balance (in shares) at Mar. 31, 2018 | 3,368,438 | ||||
Balance at Mar. 31, 2018 | $ 3,369 | 94,585,965 | (64,868,850) | 29,720,484 | |
Balance (in shares) at Dec. 31, 2018 | 3,376,230 | ||||
Balance at Dec. 31, 2018 | $ 3,377 | 95,532,881 | (79,924,699) | 15,611,559 | |
Series A cumulative preferred dividends | |||||
Stock-based compensation expense | 91,204 | 91,204 | |||
Net loss | (2,747,809) | (2,747,809) | |||
Balance (in shares) at Mar. 31, 2019 | 3,376,230 | ||||
Balance at Mar. 31, 2019 | $ 3,377 | $ 95,624,085 | $ (82,672,508) | $ 12,954,954 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating activities: | ||
Net loss | $ (2,747,809) | $ (3,313,961) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 18,272 | 28,018 |
Stock-based compensation expense | 91,204 | 324,667 |
Change in deferred income taxes | (150,352) | |
Non-cash interest expense | 1,356 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses, deposits and other assets | (119,644) | (92,944) |
Accounts payable, accrued expenses and other liabilities | 250,871 | (236,420) |
Net cash used in operating activities | (2,657,458) | (3,289,284) |
Cash flows provided by financing activities: | ||
Proceeds from the sale of common stock | 10,846,062 | |
Payment of offering costs | (253,765) | |
Net cash provided by financing activities | 10,592,297 | |
Net (decrease) increase in cash and cash equivalents | (2,657,458) | 7,303,013 |
Cash and cash equivalents at beginning of period | 7,991,172 | 8,896,468 |
Cash and cash equivalents at end of period | 5,333,714 | 16,199,481 |
Supplemental disclosure of non-cash investing and financing activities: | ||
Reclassification of accrued dividends related to the issuance of common stock to the Series A convertible preferred stockholders | 1,148,307 | |
Offering costs in accounts payable and accrued expenses | 28,549 | 174,777 |
Series A cumulative preferred dividends | (85,993) | |
Operating lease right of use asset and current and noncurrent liability | $ 334,205 |
Note 1 - Organization and Descr
Note 1 - Organization and Description of Business | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization and Description of Business Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware corporation, is a clinical stage biotechnology company developing new treatments for life threatening conditions by improving the body’s ability to bring oxygen to the areas where it is needed most. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (“TSC”), for use in those life threatening conditions in which cellular oxygen deprivation (“hypoxia”) is the basis for significant unmet medical needs. TSC is designed to safely and selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in many indications, including oncology and cardiovascular/stroke. In cancer, TSC re-oxygenates treatment-resistant cancerous tissue, making the cancer cells up to three 529, may 529 PI3K/Akt/mTOR two 1 529 On December 13, 2018, 1 15 fifteen one No 2015 |
Note 2 - Liquidity
Note 2 - Liquidity | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Liquidity [Text Block] | 2. Liquidity The Company has not No The Company currently does not may third may not The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company’s ability to continue as a going concern. The Company currently has no may not not March 31, 2019 July 2019. Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. |
Note 3 - Basis of Presentation
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's Form 10 December 31, 2018, March 19, 2019, not Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X March 31, 2019, three March 31, 2019 2018. three March 31, 2019 not may December 31, 2019. not December 31, 2018 10 March 19, 2019. Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results may Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. Intangible Asset The Company's RES- 529 October 1 no 529 three March 31, 2019 2018. Research and Development Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company’s behalf). Costs incurred for research and development are expensed as incurred. At the end of the reporting period, the Company compares payments made to third may third Leases In February 2016, 7 Net Loss Per Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of Common Stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of March 31, 2019 2018 March 31, 2019 2018 Convertible debt — 14,325 Common stock warrants 2,087,012 2,113,815 Stock options 256,057 203,586 Unvested restricted stock awards — 102 2,343,069 2,331,828 Amounts in the table reflect the Common Stock equivalents of the noted instruments. Recently Issued But Not In August 2018, 2018 13, Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, 820. 820's December 15, 2019 Recently Adopted Accounting Pronouncements In February 2016, 2016 02, Leases (Topic 842 842, The Company adopted ASC 842, January 1, 2019 not 842 $0.3 On January 1, 2019, 2018 07, Compensation—Stock Compensation (Topic 718 No. 2018 07” 505 50 Equity-based Payments to Non-employees 718 all No. 2018 17 not |
Note 4 - Accrued Expenses and O
Note 4 - Accrued Expenses and Other Current Liabilities | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 4. Other Accrued Expenses and Liabilities Other accrued expenses and liabilities consisted of the following: March 31, 2019 December 31, 2018 Accrued payroll and payroll related expenses 258,877 409,889 Accrued professional fees 96,124 69,231 Accrued clinical studies expenses 170,755 34,000 Other accrued expenses 77,692 92,106 Total $ 603,448 $ 605,226 |
Note 5 - Stockholders' Equity a
Note 5 - Stockholders' Equity and Common Stock Warrants | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 5. Stockholders' Equity and Common Stock Warrants 2018 In January 2018, 1,000,000 1,000,000 $12.00 $10.8 150,000 150,000 131,375 $12.00 In addition, at the closing, the Company issued to designees of the underwriter warrants to purchase up to 50,000 $15.00 five During its evaluation of equity classification for the Common Stock warrants, the Company considered the conditions as prescribed within ASC 815 40, Derivatives and Hedging, Contracts in an Entity’s own Equity 815 40” 815 40 not not 480 Distinguishing Liabilities from Equity not not 815, As a result of the Company's Common Stock offering in January 2018, 1,400,462 553,752 68,815 777,895 $8.2 Common Stock Warrants As of March 31, 2019, Outstanding Range of exercise price per share Expiration dates Common stock warrants issued before 2016 1,767 $562.50 - $735.00 2019 Common stock warrants issued in 2017 related to Series A convertible preferred stock offering 903,870 $33.30 March 2022 Common stock warrants issued in 2018 related to the common stock offering 1,181,375 $12.00 - $15.00 January 2023 2,087,012 During the three March 31, 2019, no no |
Note 6 - Stock-based Compensati
Note 6 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 6. Stock-Based Compensation 2015 The Diffusion Pharmaceuticals Inc. 2015 "2015 January 1 4.0% December 31, 135,049 January 1, 2019, may 2015 March 31, 2019, 77,340 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated: Three Months Ended March 31, 2019 2018 Research and development $ 13,596 $ 16,372 General and administrative 77,608 308,295 Total stock-based compensation expense $ 91,204 $ 324,667 The following table summarizes the activity related to all stock option grants for the three March 31, 2019: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2019 203,736 $ 88.14 $ 143 Granted 59,670 2.10 Forfeited (7,202 ) 123.38 Expired (147 ) 276.00 Outstanding at March 31, 2019 256,057 $ 66.99 7.19 $ 96,716 Exercisable at March 31, 2019 175,720 $ 93.36 6.19 $ 8,651 The weighted average grant date fair value of stock option awards granted was $1.77 three March 31, 2019. three March 31, 2019 2018 $0.2 $0.3 No March 31, 2019, $0.6 1.51 Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three 2019 Expected term (in years) 5.77 Risk-free interest rate 2.5 % Expected volatility 114.4 % Dividend yield — |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 7. Commitments and Contingencies Office Space Rental The Company has a non-cancelable operating lease for office and laboratory space in Charlottesville, Virginia, which began in April 2017 March 31, 2019, 3.1 3, 842 first 2019 $0.1 $0.2 842 10%. second 2022 5 not March 31, 2019. Rent expense related to the Company's operating lease was approximately $20,000 $28,000 three March 31, 2019 2018, March 31, 2019: Rental Commitments March 31, 2019 2019 $ 86,149 2020 116,464 2021 118,519 2022 39,735 Total 360,867 Less: imputed interest 47,503 Current and noncurrent operating lease liability $ 313,364 Future minimum rental payments under the Company's non-cancelable operating lease was as follows as of December 31, 2018: Rental Commitments December 31, 2018 2019 $ 114,409 2020 116,464 2021 118,519 2022 39,735 Total $ 389,127 Research and Development Arrangements In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may Legal Proceedings On August 7, 2014, Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, November 19, 2018 not November 2019. may |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X March 31, 2019, three March 31, 2019 2018. three March 31, 2019 not may December 31, 2019. not December 31, 2018 10 March 19, 2019. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim condensed consolidated financial statements, actual results may |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. |
Goodwill and Intangible Assets, Policy [Policy Text Block] | Intangible Asset The Company's RES- 529 October 1 no 529 three March 31, 2019 2018. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company’s behalf). Costs incurred for research and development are expensed as incurred. At the end of the reporting period, the Company compares payments made to third may third |
Lessee, Leases [Policy Text Block] | Leases In February 2016, 7 |
Income Tax, Policy [Policy Text Block] | Net Loss Per Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of Common Stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of March 31, 2019 2018 March 31, 2019 2018 Convertible debt — 14,325 Common stock warrants 2,087,012 2,113,815 Stock options 256,057 203,586 Unvested restricted stock awards — 102 2,343,069 2,331,828 Amounts in the table reflect the Common Stock equivalents of the noted instruments. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued But Not In August 2018, 2018 13, Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, 820. 820's December 15, 2019 Recently Adopted Accounting Pronouncements In February 2016, 2016 02, Leases (Topic 842 842, The Company adopted ASC 842, January 1, 2019 not 842 $0.3 On January 1, 2019, 2018 07, Compensation—Stock Compensation (Topic 718 No. 2018 07” 505 50 Equity-based Payments to Non-employees 718 all No. 2018 17 not |
Note 3 - Basis of Presentatio_2
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | March 31, 2019 2018 Convertible debt — 14,325 Common stock warrants 2,087,012 2,113,815 Stock options 256,057 203,586 Unvested restricted stock awards — 102 2,343,069 2,331,828 |
Note 4 - Accrued Expenses and_2
Note 4 - Accrued Expenses and Other Current Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Other Current Liabilities [Table Text Block] | March 31, 2019 December 31, 2018 Accrued payroll and payroll related expenses 258,877 409,889 Accrued professional fees 96,124 69,231 Accrued clinical studies expenses 170,755 34,000 Other accrued expenses 77,692 92,106 Total $ 603,448 $ 605,226 |
Note 5 - Stockholders' Equity_2
Note 5 - Stockholders' Equity and Common Stock Warrants (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block] | <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="4" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise price per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 6%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued before 2016</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,767</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$562.50</div></td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">-</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$735.00</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" rowspan="1" style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2019</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">903,870</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td colspan="2" nowrap="nowrap" rowspan="1" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; padding: 0px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33.30</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,181,375</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.00</div></td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">-</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.00</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,087,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 6%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 7%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> </tr> </table></div>" id="sjs-B4"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="4" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise price per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 6%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Expiration dates</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued before 2016</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,767</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$562.50</div></td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">-</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$735.00</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" rowspan="1" style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2019</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">903,870</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td colspan="2" nowrap="nowrap" rowspan="1" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; padding: 0px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33.30</div></td> <td nowrap="nowrap" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,181,375</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.00</div></td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">-</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.00</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,087,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 6%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 7%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> </tr> </table></div> |
Note 6 - Stock-based Compensa_2
Note 6 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, 2019 2018 Research and development $ 13,596 $ 16,372 General and administrative 77,608 308,295 Total stock-based compensation expense $ 91,204 $ 324,667 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2019 203,736 $ 88.14 $ 143 Granted 59,670 2.10 Forfeited (7,202 ) 123.38 Expired (147 ) 276.00 Outstanding at March 31, 2019 256,057 $ 66.99 7.19 $ 96,716 Exercisable at March 31, 2019 175,720 $ 93.36 6.19 $ 8,651 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Expected term (in years) 5.77 Risk-free interest rate 2.5 % Expected volatility 114.4 % Dividend yield — |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Rental Commitments March 31, 2019 2019 $ 86,149 2020 116,464 2021 118,519 2022 39,735 Total 360,867 Less: imputed interest 47,503 Current and noncurrent operating lease liability $ 313,364 Rental Commitments December 31, 2018 2019 $ 114,409 2020 116,464 2021 118,519 2022 39,735 Total $ 389,127 |
Note 1 - Organization and Des_2
Note 1 - Organization and Description of Business (Details Textual) | Dec. 13, 2018 |
Reverse Stock Split [Member ] | |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 |
Note 3 - Basis of Presentatio_3
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($) | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 01, 2019 | Dec. 31, 2018 | |
Impairment of Intangible Assets (Excluding Goodwill), Total | $ 0 | $ 0 | ||
Operating Lease, Right-of-Use Asset | 313,364 | |||
Operating Lease, Liability, Total | $ 313,364 | |||
Accounting Standards Update 2016-02 [Member] | ||||
Operating Lease, Right-of-Use Asset | $ 300,000 | |||
Operating Lease, Liability, Total | $ 300,000 |
Note 3 - Basis of Presentatio_4
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Anti-dilutive securities (in shares) | 2,343,069 | 2,331,828 |
Convertible Debt Securities [Member] | ||
Anti-dilutive securities (in shares) | 14,325 | |
Warrant [Member] | ||
Anti-dilutive securities (in shares) | 2,087,012 | 2,113,815 |
Share-based Payment Arrangement, Option [Member] | ||
Anti-dilutive securities (in shares) | 256,057 | 203,586 |
Restricted Stock [Member] | ||
Anti-dilutive securities (in shares) | 102 |
Note 4 - Accrued Expenses and_3
Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Accrued payroll and payroll related expenses | $ 258,877 | $ 409,889 |
Accrued professional fees | 96,124 | 69,231 |
Accrued clinical studies expenses | 170,755 | 34,000 |
Other accrued expenses | 77,692 | 92,106 |
Total | $ 603,448 | $ 605,226 |
Note 5 - Stockholders' Equity_3
Note 5 - Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | |
Jan. 31, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | |
Stock Issued During Period, Shares, Conversion of Convertible Securities | 553,752 | ||
Common Stock Dividends, Shares | 68,815 | ||
Stock Issued During Period, Shares, Make-whole Adjustment | 777,895 | ||
Dividends, Make-whole Adjustment | $ 8,200,000 | $ 8,167,895 | |
Class of Warrant or Rights, Expired | 0 | ||
Class of Warrant or Right, Exercised | 0 | ||
Conversion From Series A Preferred Stock to Common Stock [Member] | |||
Conversion of Stock, Shares Issued | 1,400,462 | ||
Warrants Issued in Connection with the January 2018 Offering [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,000,000 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 12 | ||
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 15 | ||
Option Warrants [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 150,000 | ||
Additional Warrants [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 12 | ||
Class of Warrant or Right, Granted | 131,375 | ||
Underwriter Warrants [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 15 | ||
Class of Warrant or Right, Term | 5 years | ||
Underwriter Warrants [Member] | Maximum [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 50,000 | ||
January 2018 Offering [Member] | |||
Stock Issued During Period, Shares, New Issues | 1,000,000 | ||
Proceeds from Issuance or Sale of Equity, Total | $ 10,800,000 | ||
Stock Issued During Period, Shares, Issued for Services | 150,000 |
Note 5 - Stockholders' Equity_4
Note 5 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares | Mar. 31, 2019 | Jan. 31, 2018 |
Common stock warrants, outstanding (in shares) | 2,087,012 | |
Warrants issued before 2016 [Member] | ||
Common stock warrants, outstanding (in shares) | 1,767 | |
Warrants issued before 2016 [Member] | Minimum [Member] | ||
Range of exercise price (in dollars per share) | $ 562.50 | |
Warrants issued before 2016 [Member] | Maximum [Member] | ||
Range of exercise price (in dollars per share) | $ 735 | |
Warrants Attached to Series A Convertible Preferred Stock [Member] | ||
Common stock warrants, outstanding (in shares) | 903,870 | |
Range of exercise price (in dollars per share) | $ 33.30 | |
Warrants Issued in Connection with the January 2018 Offering [Member] | ||
Common stock warrants, outstanding (in shares) | 1,181,375 | |
Range of exercise price (in dollars per share) | $ 12 | |
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member] | ||
Range of exercise price (in dollars per share) | $ 12 | |
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member] | ||
Range of exercise price (in dollars per share) | $ 15 |
Note 6 - Stock-based Compensa_3
Note 6 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions | Jan. 01, 2019 | Mar. 31, 2019 | Mar. 31, 2018 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 0 | 0 | |
Share-based Payment Arrangement, Option [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.77 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 0.2 | $ 0.3 | |
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 0.6 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 1 year 186 days | ||
Equity Incentive Plan 2015 [Member] | |||
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis | 4.00% | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 135,049 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 77,340 |
Note 6 - Stock-based Compensa_4
Note 6 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Stock-based compensation expense | $ 91,204 | $ 324,667 |
Research and Development Expense [Member] | ||
Stock-based compensation expense | 13,596 | 16,372 |
General and Administrative Expense [Member] | ||
Stock-based compensation expense | $ 77,608 | $ 308,295 |
Note 6 - Stock-based Compensa_5
Note 6 - Stock-based Compensation - Stock Option Activity (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Options outstanding, number (in shares) | 203,736 | |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 88.14 | |
Options outstanding, aggregate intrinsic value | $ 96,716 | $ 143 |
Granted (in shares) | 59,670 | |
Granted, weighted-average exercise price (in dollars per share) | $ 2.10 | |
Forfeited (in shares) | (7,202) | |
Forfeited, weighted-average exercise price (in dollars per share) | $ 123.38 | |
Expired (in shares) | (147) | |
Expired, weighted-average exercise price (in dollars per share) | $ 276 | |
Options outstanding, number (in shares) | 256,057 | |
Options outstanding, weighted-average exercise price (in dollars per share) | $ 66.99 | |
Options outstanding, weighted-average remaining contractual life (Year) | 7 years 69 days | |
Options outstanding, aggregate intrinsic value | $ 96,716 | $ 143 |
Exercisable (in shares) | 175,720 | |
Exercisable, weighted-average exercise price (in dollars per share) | $ 93.36 | |
Exercisable, weighted-average remaining contractual life (Year) | 6 years 69 days | |
Exercisable, aggregate intrinsic value | $ 8,651 |
Note 6 - Stock-based Compensa_6
Note 6 - Stock-based Compensation - Fair Value Assumptions (Details) - Minimum [Member] | 3 Months Ended |
Mar. 31, 2019 | |
Expected term (Year) | 5 years 281 days |
Risk-free interest rate | 2.50% |
Expected volatility | 114.40% |
Note 7 - Commitments and Cont_3
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Operating Lease, Remaining Lease Term | 3 years 36 days | ||
Operating Lease, Liability, Current | $ 110,001 | ||
Operating Lease, Liability, Noncurrent | $ 203,363 | ||
Lessee, Operating Lease, Discount Rate | 10.00% | ||
Lessee, Operating Lease, Renewal Term | 5 years | ||
Operating Lease, Expense | $ 20,000 | $ 28,000 |
Note 7 - Commitments and Cont_4
Note 7 - Commitments and Contingencies - Future Minimum Rental Payments (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
2019 | $ 86,149 | |
2020 | 116,464 | $ 116,464 |
2021 | 118,519 | 118,519 |
2022 | 39,735 | 39,735 |
Total | 360,867 | 389,127 |
Less: imputed interest | 47,503 | |
Current and noncurrent operating lease liability | $ 313,364 | |
2019 | $ 114,409 |